{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:05:51Z","timestamp":1777878351911,"version":"3.51.4"},"reference-count":50,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Takeda (China) International Trading Company"},{"name":"CAMS Innovation Fund for Medical Sciences","award":["CIFMS, No. 2023-I2M-2-007"],"award-info":[{"award-number":["CIFMS, No. 2023-I2M-2-007"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>Von Willebrand disease (VWD) is an inherited bleeding disorder resulting from a deficiency in von Willebrand factor (VWF), either quantitative or qualitative. Recombinant VWF (rVWF) presents a novel therapeutic option for patients with VWD. Produced in Chinese hamster ovary cells, rVWF is free of animal or human plasma proteins, thus eliminating the risk of pathogen transmission. It preserves the full range of VWF multimers, including ultra-large multimers, which are essential for hemostasis. Research indicates that rVWF demonstrates superior pharmacokinetics and pharmacodynamics compared to plasma-derived VWF, offering a longer terminal half-life, enhanced platelet adhesion and aggregation, and more robust factor VIII stabilization. These properties contribute to rVWF\u2019s increased hemostatic efficacy in managing bleeding episodes and perioperative surgical bleeding in adults and children with VWD, as well as the routine prophylaxis for adults to reduce the frequency of bleeding episodes. Furthermore, rVWF is well-tolerated with a low thrombotic risk, making it a promising treatment option and addressing a significant clinical need globally.<\/jats:p>","DOI":"10.1177\/20406207261419941","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:04:37Z","timestamp":1770984277000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Recombinant von Willebrand factor for von Willebrand disease: mechanism of action and clinical application"],"prefix":"10.1177","volume":"17","author":[{"given":"Zhengjie","family":"Hua","sequence":"first","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology &amp; Blood Diseases Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin, China"},{"name":"Tianjin Institutes of Health Science, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Institute of Hematology &amp; Blood Diseases Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Institute of Hematology &amp; Blood Diseases Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3741-8518","authenticated-orcid":false,"given":"Renchi","family":"Yang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology &amp; Blood Diseases Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin 300020, China"},{"name":"Tianjin Institutes of Health Science, 28 Tuanbo Road, Tianjin 301600, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003264"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000563"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092351"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050184"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-949668"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000065"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1757183"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S389241"},{"key":"e_1_3_4_10_2","unstructured":"National Health Commission of the People's Republic of China. Second rare diseases catalog [in Chinese] https:\/\/www.nhc.gov.cn\/wjw\/c100375\/202309\/8d3e73289a6b4882996dbd1ed66780aa.shtml (2023 accessed 6 February 2026)."},{"key":"e_1_3_4_11_2","first-page":"1","article-title":"Chinese guideline on the diagnosis and management of Von Willebrand disease (2022) [in Chinese]","volume":"43","author":"Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association","year":"2022","unstructured":"Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guideline on the diagnosis and management of Von Willebrand disease (2022) [in Chinese]. Zhonghua Xue Ye Xue Za Zhi 2022; 43: 1\u20136.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"e_1_3_4_12_2","article-title":"Desmopressin as a treatment in patients with Von Willebrand disease: a systematic review","volume":"15","author":"Beltran A","year":"2023","unstructured":"Beltran A, Jaramillo AP, Vallejo MP, et al. Desmopressin as a treatment in patients with Von Willebrand disease: a systematic review. Cureus 2023; 15: e44310.","journal-title":"Cureus"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.91a.22033"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2023.2268282"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1255445"},{"key":"e_1_3_4_16_2","article-title":"Development of a plasma- and albumin-free recombinant von Willebrand factor","volume":"29","author":"Turecek PL","year":"2009","unstructured":"Turecek PL, Mitterer A, Matthiessen HP, et al. Development of a plasma- and albumin-free recombinant von Willebrand factor. Hamostaseologie 2009; 29(Suppl 1): S32\u2013S38.","journal-title":"Hamostaseologie"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00418-001-0375-x"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e3283254570"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1661533"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S377126"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00893.x"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2019000064"},{"key":"e_1_3_4_23_2","first-page":"349","article-title":"The super glue of ultra-large multimers - characterisation of recombinant and platelet derived von Willebrand factor","volume":"4","author":"Kragh T","year":"2020","unstructured":"Kragh T, Spannagl M, Ott HW, et al. The super glue of ultra-large multimers - characterisation of recombinant and platelet derived von Willebrand factor. Res Pract Thromb Haemost 2020; 4: 349.","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2025.103169"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-479527"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629873"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14313"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014810"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13949"},{"key":"e_1_3_4_30_2","first-page":"272","article-title":"Phase 3 study evaluating recombinant von willebrand factor in children with von Willebrand disease","volume":"9","author":"Shayla B","year":"2025","unstructured":"Shayla B, Amy D, Pascual MV, et al. Phase 3 study evaluating recombinant von willebrand factor in children with von Willebrand disease. Res Pract Thromb Haemost. 2025; 9: 272\u2013274.","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_3_4_31_2","author":"Takeda","year":"2025","unstructured":"Takeda. VONVENDI [von Willebrand factor (recombinant)] prescribing information. 2025.","journal-title":"VONVENDI [von Willebrand factor (recombinant)] prescribing information"},{"key":"e_1_3_4_32_2","author":"Octapharma","year":"2024","unstructured":"Octapharma. WILATE (von Willebrand Factor\/Coagulation Factor VIII Complex (Human)) prescribing information. 2024.","journal-title":"WILATE (von Willebrand Factor\/Coagulation Factor VIII Complex (Human)) prescribing information"},{"key":"e_1_3_4_33_2","author":"Behring C.","year":"2020","unstructured":"Behring C. HUMATE-P [Antihemophilic Factor\/von Willebrand Factor Complex (Human)] prescribing information. 2020.","journal-title":"HUMATE-P [Antihemophilic Factor\/von Willebrand Factor Complex (Human)] prescribing information"},{"key":"e_1_3_4_34_2","author":"Grifols","year":"2024","unstructured":"Grifols. Willfact(human von Willebrand factor) prescribing information. 2024.","journal-title":"Willfact(human von Willebrand factor) prescribing information"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01435.x"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14892"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003265"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.11.3150.bloodjournal85113150"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpc.2010.07.002"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1021\/jp5022664"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.5482\/HAMO-14-12-0077"},{"key":"e_1_3_4_42_2","article-title":"The role of ultralarge multimers in recombinant human von Willebrand factor - a review of physico-and biochemical studies and findings in in vivo models and in humans with von Willebrand disease","volume":"37","author":"Turecek PL","year":"2017","unstructured":"Turecek PL, Spannagl M, Kragh T, et al. The role of ultralarge multimers in recombinant human von Willebrand factor - a review of physico-and biochemical studies and findings in in vivo models and in humans with von Willebrand disease. Hamostaseologie 2017; 37: S15\u2013S25.","journal-title":"Hamostaseologie"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14242"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2023.2184339"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1177\/10760296231177294"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2019000368"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70032"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010716"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1779485"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2025.07.013"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024209"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261419941","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207261419941","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261419941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:18:14Z","timestamp":1777591094000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207261419941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":50,"alternative-id":["10.1177\/20406207261419941"],"URL":"https:\/\/doi.org\/10.1177\/20406207261419941","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"20406207261419941"}}